DE69434640D1 - Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe - Google Patents

Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe

Info

Publication number
DE69434640D1
DE69434640D1 DE69434640T DE69434640T DE69434640D1 DE 69434640 D1 DE69434640 D1 DE 69434640D1 DE 69434640 T DE69434640 T DE 69434640T DE 69434640 T DE69434640 T DE 69434640T DE 69434640 D1 DE69434640 D1 DE 69434640D1
Authority
DE
Germany
Prior art keywords
sustained release
insoluble drugs
hydrogel systems
hydrophobic polymer
gelling agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69434640T
Other languages
English (en)
Other versions
DE69434640T2 (de
Inventor
Anand R Baichwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penwest Pharmaceuticals Co
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Application granted granted Critical
Publication of DE69434640D1 publication Critical patent/DE69434640D1/de
Publication of DE69434640T2 publication Critical patent/DE69434640T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
DE69434640T 1993-09-09 1994-08-30 Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe Expired - Fee Related DE69434640T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US118924 1993-09-09
US08/118,924 US5455046A (en) 1993-09-09 1993-09-09 Sustained release heterodisperse hydrogel systems for insoluble drugs

Publications (2)

Publication Number Publication Date
DE69434640D1 true DE69434640D1 (de) 2006-04-27
DE69434640T2 DE69434640T2 (de) 2006-08-10

Family

ID=22381584

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69428853T Expired - Lifetime DE69428853T2 (de) 1993-09-09 1994-08-30 Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe
DE69434640T Expired - Fee Related DE69434640T2 (de) 1993-09-09 1994-08-30 Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe
DE0642785T Pending DE642785T1 (de) 1993-09-09 1994-08-30 Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69428853T Expired - Lifetime DE69428853T2 (de) 1993-09-09 1994-08-30 Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0642785T Pending DE642785T1 (de) 1993-09-09 1994-08-30 Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe.

Country Status (11)

Country Link
US (6) US5455046A (de)
EP (2) EP1101489B1 (de)
JP (1) JP4077886B2 (de)
AT (2) ATE318586T1 (de)
CA (1) CA2131647C (de)
DE (3) DE69428853T2 (de)
DK (1) DK0642785T3 (de)
ES (2) ES2070810T3 (de)
GR (1) GR950300035T1 (de)
IL (1) IL110744A (de)
PT (2) PT642785E (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CN100998869A (zh) 1993-07-19 2007-07-18 血管技术药物公司 抗血管生长组合物及使用方法
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5399362A (en) * 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
JP3279318B2 (ja) * 1994-04-25 2002-04-30 ペンウェスト ファーマシューティカルズ カンパニー 持続放出性賦形剤
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
AU770001B2 (en) * 1996-04-18 2004-02-12 Penwest Pharmaceutical Co. Sustained release heterodisperse hydrogel systems - amorphous drugs
EP1616563A3 (de) * 1996-05-24 2006-01-25 Angiotech Pharmaceuticals, Inc. Perivaskuläre Verabreichung anti-angiogener Faktoren zur Behandlung oder Prävention von Gefässerkrankungen
WO1998001117A1 (en) * 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6416786B1 (en) 1998-12-11 2002-07-09 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
AU762291B2 (en) * 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
USD432121S (en) * 1999-12-13 2000-10-17 E-Lead Electronics Co., Ltd. Holder for a mobile telephone for an automobile
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
BR0016707A (pt) 1999-12-23 2002-09-03 Pfizer Prod Inc Forma de dosagem de droga em camadas acionada por hidrogel
US7056531B1 (en) 2000-05-04 2006-06-06 Nature's Way Products, Inc. Sustained release compositions for orally administered substances and methods
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
ES2269441T3 (es) * 2000-06-27 2007-04-01 F. Hoffmann-La Roche Ag Metodo para la preparacion de una composicion.
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
MXPA03001406A (es) 2000-08-15 2004-05-04 Surmodics Inc Matriz de incorporacion de medicamento.
JP2004513091A (ja) * 2000-10-03 2004-04-30 ペンウェスト　ファーマシューティカルズ　カンパニー 異なる速度の複数の医薬活性成分の送達系
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
EP1752189A3 (de) * 2001-04-20 2007-02-21 Alza Corporation Mikroprojektionsanordnung mit einem Überzug, der ein vorteilhaftes Mittel enthält
WO2002085447A2 (en) * 2001-04-20 2002-10-31 Alza Corporation Microprojection array having a beneficial agent containing coating
EP1404331B1 (de) * 2001-07-06 2007-10-31 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
EP2311460A1 (de) 2001-07-06 2011-04-20 Endo Pharmaceuticals Inc. Kontrolliert freisetzende Formulierungen von Oxymorphon
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
MXPA04009701A (es) * 2002-04-05 2005-05-27 Penwest Pharmaceuticals Co Formulaciones de metoprolol de liberacion sostenida.
WO2004012715A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
KR100548925B1 (ko) * 2002-10-23 2006-02-02 한미약품 주식회사 약물의 경구투여용 서방성 조성물
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
SI1685829T1 (sl) * 2002-11-22 2008-08-31 Gruenenthal Gmbh Uporaba (1RS,3RS,6RS)-6-dimetilaminometil-1- (3-metoksi-fenil)-cikloheksan-1, 3-diola za zdravljenje vnetne bolečine
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
BRPI0417621A (pt) * 2003-12-17 2007-04-10 Pfizer Prod Inc terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
US20060004076A1 (en) * 2004-06-30 2006-01-05 Inflabloc Pharmaceuticals, Inc. Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
EP1830886B1 (de) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Verfahren zur stabilisierung eines arzneimittels gegen demenz
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
MX2008000084A (es) * 2005-06-29 2008-03-18 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion sostenida y procedimientos de las mismas.
EP1743638A1 (de) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmazeutische Formulierungen von substituierten Pyrazolinderivaten
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US20080069889A1 (en) * 2006-03-07 2008-03-20 Cherukuri S R Compressible resilient granules and formulations prepared therefrom
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
JP4720620B2 (ja) * 2006-05-30 2011-07-13 コニカミノルタビジネステクノロジーズ株式会社 カール補正装置及びこれを備えた画像形成装置
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
US20080085305A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone
US20080085304A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
CN101588794A (zh) * 2007-01-25 2009-11-25 万能药生物有限公司 调节释放药物组合物及其制备方法
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
CA2732131A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
ES2719900T3 (es) 2008-09-05 2019-07-16 Gruenenthal Gmbh Combinación farmacéutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y pregabalina o gabapentina
GB0817120D0 (en) * 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
JP5433295B2 (ja) * 2009-05-01 2014-03-05 高田製薬株式会社 キサンタンガム被覆水溶性糖類及び圧縮成形製剤
US20110053914A1 (en) 2009-08-28 2011-03-03 Gruenenthal Gmbh Pharmaceutical Combination Comprising 6-Dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-Dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an Antiepileptic
AR081931A1 (es) 2010-06-15 2012-10-31 Gruenenthal Gmbh Combinacion farmaceutica
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
EP2827839B1 (de) 2012-03-20 2019-02-27 Particle Dynamics International, LLC Dosierungsform auf basis eines gelierungsmittels
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
EP3316862A4 (de) 2015-07-02 2019-02-06 University of Louisville Research Foundation, Inc. Aus essbarer pflanze erlangte mikrovesikelzusammensetzungen zur abgabe von mirna und verfahren zur behandlung von krebs

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) * 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
SU432703A3 (de) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
JPS5630485A (en) * 1979-08-21 1981-03-27 Sansho Kk Heat insulation composition for heating and cooling
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
JPS60139688A (ja) * 1983-12-28 1985-07-24 Tokyo Tanabe Co Ltd 無定形ジヒドロピリジン粉末製剤
DE3400106A1 (de) * 1984-01-04 1985-07-11 Klaus-Dieter Dr. 3550 Marburg Bremecker Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung
KR850700212A (ko) * 1984-03-21 1985-12-26 죠지 드모트 서방성 약제학적 캼셀제
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
DE3682208D1 (de) * 1986-12-18 1991-11-28 Kurt Heinz Bauer Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US5288500A (en) * 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
GB8722306D0 (en) * 1987-09-22 1987-10-28 Aps Research Ltd Sustained-release formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JP2668730B2 (ja) * 1988-03-09 1997-10-27 雪印乳業株式会社 天然ポリマーを用いた徐放性製剤
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments

Also Published As

Publication number Publication date
ES2070810T3 (es) 2001-12-16
DE69428853D1 (de) 2001-12-06
IL110744A (en) 1998-12-27
US6136343A (en) 2000-10-24
US5512297A (en) 1996-04-30
EP0642785B1 (de) 2001-10-31
DK0642785T3 (da) 2001-12-31
US5455046A (en) 1995-10-03
PT1101489E (pt) 2006-05-31
DE69428853T2 (de) 2002-04-11
EP1101489A3 (de) 2001-09-19
EP1101489B1 (de) 2006-03-01
JPH07165615A (ja) 1995-06-27
CA2131647C (en) 1999-08-10
EP0642785A3 (de) 1996-11-06
DE69434640T2 (de) 2006-08-10
ATE207742T1 (de) 2001-11-15
US5667801A (en) 1997-09-16
ES2070810T1 (es) 1995-06-16
ATE318586T1 (de) 2006-03-15
JP4077886B2 (ja) 2008-04-23
GR950300035T1 (en) 1995-07-31
ES2254274T3 (es) 2006-06-16
DE642785T1 (de) 1995-09-28
CA2131647A1 (en) 1995-03-10
EP0642785A2 (de) 1995-03-15
PT642785E (pt) 2002-02-28
US5554387A (en) 1996-09-10
US5846563A (en) 1998-12-08
IL110744A0 (en) 1994-08-22
EP1101489A2 (de) 2001-05-23

Similar Documents

Publication Publication Date Title
DE69434640D1 (de) Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe
NO912769D0 (no) Avleveringssystem for medikamenter.
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
CA2313642A1 (en) Pharmaceutical hydrogel formulations, drug delivery devices and methods
WO2002000193A3 (en) Multiple stimulus reversible hydrogels
AU7534087A (en) Sustained release pharmaceutical compositions in oral dosage form
FI906344A (fi) Kontrollerat frigoerande farmaceutiskt preparat.
DK191189D0 (da) Vandig emulsion til farmaceutisk doseringsform
DE69112108D1 (de) Klebende Vorrichtung zur transdermalen Verabreichung eines Wirkstoffs.
DK0621038T3 (da) Farmaceutiske præparater indeholdende silikatpolymere
ES2029853T5 (es) Base de unguento y unguento.
IT8848675A0 (it) Granuli a base di polimeri idrofili impregnati con una formulazione acquosa contenente uno o piu' principi attivi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee